1-20 of 72
Krish Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Yasmin H. Karimi, Rajat Bannerji, Loretta Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy Bartlett, Victoria Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua Brody, Jeremy S. Abramson, Matthew Lunning, Nirav N. Shah, Ayed Ayed, Manali Kamdar, Benjamin Parsons, Paolo Caimi, Ian Flinn, Alex Herrera, Jeffrey Sharman, Marshall McKenna, Philippe Armand, Brad Kahl, Sonali Smith, Andrew Zelenetz, Lihua Elizabeth Budde, Martin Hutchings, Tycel Phillips, Michael Dickinson
Journal: Blood
Blood (2024) 143 (16): 1565–1575.
https://doi.org/10.1182/blood.2023022432
Published: 2024
Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Catherine C. Coombs, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Ian W. Flinn, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Koji Izutsu, Wojciech Jurczak, William G. Wierda, Angely Loubert, Nalin Payakachat, Lisa M. Hess, Paolo Abada, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 6535.
https://doi.org/10.1182/blood-2023-186145
Published: 2023
Journal Articles

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Timothy Voorhees, Eric McLaughlin, Pallawi Torka, Jorge A Florindez, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish R. Ayyappan, Lauren Kelly Shea, Matthew J Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal H. Desai, Praveen Ramakrishnan Geethakumari, Natalie S. Grover, Narendranath Epperla
Journal: Blood
Blood (2023) 142 (Supplement 1): 3061.
https://doi.org/10.1182/blood-2023-181056
Published: 2023
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Pier Luigi Zinzani, Michael L. Wang, Sunita D. Nasta, Ewa Lech-Maranda, Yoshiaki Ogawa, Bita Fakhri, Bryone Kuss, Kaname Miyashita, Krish Patel, Catherine C. Coombs, Shuo Ma, Manish Patel, Minal A. Barve, Benoit Tessoulin, Anastasios Stathis, Won Seog Kim, Daisuke Ennishi, Daigo Hashimoto, Kensuke Kojima, Andrew D. Zelenetz, Jonathon B. Cohen, Julie M. Vose, Kami J. Maddocks, Talha Munir, Fangfang Sun, Faith Bian, Donald E. Tsai, Paolo Abada, Chan Y. Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 3026.
https://doi.org/10.1182/blood-2023-181309
Published: 2023
Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4463.
https://doi.org/10.1182/blood-2023-179872
Published: 2023
Journal Articles

Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Andrew J. Cowan, Krish Patel, Jakub Svoboda, Bijal D. Shah, Bruce D. Cheson, Georges Azzi, Viral Rabara, Lori S. Muffly, Heidi Simmons, Stephen Thuillier, Jessica T. Leonard
Journal: Blood
Blood (2023) 142 (Supplement 1): 3777.
https://doi.org/10.1182/blood-2023-187586
Published: 2023
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Jonathon B. Cohen, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y. Cheah, Toby A. Eyre, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D. Nasta, Ian W. Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J. Alencar, David Lewis, Jennifer A. Woyach, Kami J. Maddocks, Krish Patel, Yucai Wang, Joanna M. Rhodes, Constantine S. Tam, John F. Seymour, Hirokazu Nagai, Julie M. Vose, Bita Fakhri, Marc S. Hoffmann, Francisco J. Hernandez-Ilizaliturri, Andrew D. Zelenetz, Anita Kumar, Talha Munir, Donald E. Tsai, Minna Balbas, Bin Liu, Amy S. Ruppert, Bastien Nguyen, Lindsey E. Roeker, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 981.
https://doi.org/10.1182/blood-2023-181627
Published: 2023
Journal Articles

Real-World Use and Outcomes of Therapies, Including Venetoclax-Based Treatments, after Discontinuation of a Covalent BTK Inhibitor in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nitin Jain, Toby A. Eyre, Katherine Winfree, Naleen Raj Bhandari, Manoj Khanal, Tomoko Sugihara, Paolo Abada, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 5152.
https://doi.org/10.1182/blood-2023-185758
Published: 2023
Journal Articles

A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Gerald Luscan, Luisa Paccagnella, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6250.
https://doi.org/10.1182/blood-2023-182275
Published: 2023
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Krish Patel, Julie M. Vose, Sunita D. Nasta, Jennifer R. Brown, Kami J. Maddocks, Jennifer A. Woyach, Nirav N. Shah, Bita Fakhri, Benoit Tessoulin, Shuo Ma, Deepa Jagadeesh, Ewa Lech-Maranda, Catherine C. Coombs, Manish Patel, Joanna M. Rhodes, Chaitra S Ujjani, Marc S. Hoffmann, Chan Y Cheah, Talha Munir, David Lewis, Lydia Scarfo, Toby A. Eyre, Alvaro J. Alencar, Jonathon B. Cohen, Andrew D. Zelenetz, Donald E. Tsai, Mei Li, Faith Bian, Paolo Abada, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1660.
https://doi.org/10.1182/blood-2023-180048
Published: 2023
Journal Articles

Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study

Indu Ramachandran, Sarah Rothman, Mariano Clausi, Kile Mcfadden, Brenda Salantes, Gloria Jih, Thomas Brigman, Sam Kelly, Matthew S Hall, Stephanie Yee, Iphigenia Koumenis, Poulomee Das, Jordan Briggs, Tori Braun, Ying Yuan, Elizabeth Devlin, Adrienne Farid, Nikolaus S. Trede, Tamara K. Moyo, Tahir Latif, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2023-182313
Published: 2023
Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Kaitlin Annunzio, Eric McLaughlin, Timothy Voorhees, Lauren Kelly Shea, Nuttavut Sumransub, Ashley Rose, Adam J Olszewski, Neil Bailey, Krish Patel, Tamara K. Moyo, Farrukh T. Awan, Gulrayz Ahmed, Natalie S. Grover, Adam Adika, Erica L Andres, Muhammad Salman Faisal, Beth Christian, Jacob Anna, Steven M. Bair, Nicholas Kendsersky, Colin Thomas, Pallawi Torka, Jakub Svoboda, Jordan S Carter, Mehdi Hamadani, Hayder Saeed, Sanjal H. Desai, Andrew M Evens, Narendranath Epperla
Journal: Blood
Blood (2023) 142 (Supplement 1): 382.
https://doi.org/10.1182/blood-2023-182389
Published: 2023
Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 325.
https://doi.org/10.1182/blood-2023-185852
Published: 2023
Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Evandro Bezerra, Timothy Voorhees, Ayo S Falade, Madhav R Seshadri, Megumi Bailey, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A Jacobson, Joycelynne Michelle Palmer, Annette Brown, Alex F. Herrera, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 3511.
https://doi.org/10.1182/blood-2023-182467
Published: 2023
Journal Articles

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Franck Morschhauser, Krish Patel, Sabela Bobillo, Raul Cordoba, Toby A. Eyre, Mark Bishton, Roch Houot, Hui-Lai Zhang, Liqun Zou, Wendy Osborne, Laura Gálvez-Carvajal, Catherine Thieblemont, Donald Yee, Andrea Knapp, Enkhtsetseg Purev, Haocheng Li, Vivian Chen, Karl L. Banta, Jason Sit, Emmanuel Bachy
Journal: Blood
Blood (2023) 142 (Supplement 1): 605.
https://doi.org/10.1182/blood-2023-174432
Published: 2023
Journal Articles

Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib

Alessandra Ferrajoli, George Follows, Yotvat Marmor, Shogheeg Apkarian Bourjlian, Jack Roos, Naghmana Bajwa, Venkata Madhira, Kenji Nozaki, Paulo Andre P. Palhares De Miranda, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1917.
https://doi.org/10.1182/blood-2023-174727
Published: 2023
Journal Articles

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Timothy Voorhees, Natalie S. Grover, Eric McLaughlin, Jorge A Florindez, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish R. Ayyappan, Lauren Kelly Shea, Matthew J Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal H. Desai, Praveen Ramakrishnan Geethakumari, Pallawi Torka, Narendranath Epperla
Journal: Blood
Blood (2023) 142 (Supplement 1): 900.
https://doi.org/10.1182/blood-2023-182385
Published: 2023
Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia A. Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, John C. Byrd, Emmanuelle Ferrant, Alessandra Ferrajoli, William G. Wierda, Veerendra Munugalavadla, Catherine Wangui Wachira, Chuan-Chuan Wun, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 636.
https://doi.org/10.1182/blood-2023-174750
Published: 2023
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Sowjanya Vuyyala, Andre De Menezes Silva Corraes, Megumi Bailey, Madiha Iqbal, Javier L. Munoz, Bradley Hunter, Radhika Bansal, Krish Patel, Mohamed A. Kharfan-Dabaja, Allison C. Rosenthal, Yucai Wang, Jonas Paludo, Patrick B Johnston, N. Nora Bennani, J. C. C. Villasboas, Urshila Durani, Stephen M Ansell, Yi Lin, Arushi Khurana
Journal: Blood
Blood (2023) 142 (Supplement 1): 6926.
https://doi.org/10.1182/blood-2023-188441
Published: 2023